Header Logo

GEORGE HUTTON

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Neurology
Address7200 CAMBRIDGE
Houston, TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Earla JR, Li J, Hutton GJ, Bentley JP, Aparasu RR. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 Mar 12; 85:105539. PMID: 38574721.
      Citations:    Fields:    
    2. Li J, Huang Y, Hutton GJ, Aparasu RR. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023 Sep; 11:100307. PMID: 37554927; PMCID: PMC10405092.
      Citations:    
    3. Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484. PMID: 37157135.
      Citations:    Fields:    Translation:Humans
    4. Moore MZ, P?rez CA, Hutton GJ, Patel H, Cuascut FX. Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United States. Biomedicines. 2023 Apr 20; 11(4). PMID: 37189845; PMCID: PMC10135818.
      Citations:    
    5. P?rez CA, Cuascut FX, Hutton GJ. Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update. Neurol Clin. 2023 02; 41(1):87-106. PMID: 36400561.
      Citations:    Fields:    Translation:Humans
    6. Li J, Zakeri M, Hutton GJ, Aparasu RR. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019. PMID: 35839614.
      Citations:    Fields:    
    7. Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703. PMID: 35278846.
      Citations:    Fields:    Translation:Humans
    8. Choudhury NA, Castrodad-Molina RM, Hutton GJ, Cuascut FX. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022 Feb; 58:103498. PMID: 35007821.
      Citations:    Fields:    Translation:Humans
    9. Alkabie S, Tanweer O, Hutton GJ, Cuascut FX. Clinical Reasoning: A 57-Year-Old Man With Stepwise Progressive Paraparesis, Sensory Loss, Urinary Retention, and Constipation. Neurology. 2022 02 01; 98(5):e555-e560. PMID: 34799458.
      Citations:    Fields:    Translation:Humans
    10. Talwar A, Earla JR, Hutton GJ, Aparasu RR. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308. PMID: 35158421.
      Citations:    Fields:    Translation:Humans
    11. Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, Steinmiller KC, Devine SM, Hutton GJ, Popat U, Racke MK, Georges GE, Bowen JD, Arnold DL. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Sep; 54:103149. PMID: 34284316.
      Citations: 1     Fields:    Translation:Humans
    12. Cuascut FX, Alkabie S, Hutton GJ. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103072. PMID: 34139459.
      Citations:    Fields:    Translation:Humans
    13. Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Explor Res Clin Soc Pharm. 2021 Jun; 2:100021. PMID: 35481133; PMCID: PMC9031432.
      Citations:    
    14. Earla JR, Hutton GJ, Thornton DJ, Chen H, Johnson ML, Aparasu RR. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450. PMID: 33641232.
      Citations:    Fields:    Translation:Humans
    15. Alkabie S, Castrodad-Molina R, Heck KA, Mandel J, Hutton GJ. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877. PMID: 33711579.
      Citations:    Fields:    Translation:HumansCells
    16. Mercado V, Dongarwar D, Fisher K, Salihu HM, Hutton GJ, Cuascut FX. Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis. Biomedicines. 2020 Nov 25; 8(12). PMID: 33255552; PMCID: PMC7760789.
      Citations: 1     
    17. Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Prefer Adherence. 2020; 14:2187-2199. PMID: 33177813; PMCID: PMC7649232.
      Citations: 2     
    18. Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334. PMID: 32629400.
      Citations:    Fields:    Translation:Humans
    19. Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749. PMID: 32463779; PMCID: PMC10391019.
      Citations: 1     Fields:    Translation:Humans
    20. Oh J, Achiron A, Chambers C, Derwenskus J, Devonshire V, Hellwig K, Hutton GJ, McCombe P, Moore M, Rog D, Schneider JR, Vincent SG, Chung L, Daizadeh N, Mitchell C, Compston DAS, CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators, Celius EG, Simm RF, Sousa L. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020 Aug; 43:102146. PMID: 32498033.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    21. Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines. 2020 Mar 28; 8(4). PMID: 32231060; PMCID: PMC7235875.
      Citations: 5     
    22. Earla JR, Paranjpe R, Kachru N, Hutton GJ, Aparasu RR. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676. PMID: 32171597.
      Citations:    Fields:    Translation:Humans
    23. Wang KY, Carlton J, Guffey D, Hutton GJ, Moron FE. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020 Jan; 59(1):13-20. PMID: 31715512.
      Citations: 1     Fields:    Translation:Humans
    24. Cuascut FX, Hutton GJ. Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives. Biomedicines. 2019 Mar 30; 7(2). PMID: 30935074; PMCID: PMC6631931.
      Citations: 14     
    25. Yeo CJJ, Hutton GJ, Fung SH. Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year. Radiol Case Rep. 2018 Oct; 13(5):1030-1035. PMID: 30228838; PMCID: PMC6137900.
      Citations: 3     
    26. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017 Feb 28; 88(9):842-852. PMID: 28148635; PMCID: PMC5331868.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    27. Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016 Oct 15; 369:51-52. PMID: 27653865.
      Citations: 1     Fields:    Translation:Humans
    28. Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR, Blight AR, Carrazana EJ. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. Int J MS Care. 2015 May-Jun; 17(3):138-45. PMID: 26052259; PMCID: PMC4455866.
      Citations: 6     
    29. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD, St?ve O. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb; 72(2):159-69. PMID: 25546364; PMCID: PMC5261862.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    30. Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, Hutton GJ, Birnbaum Y. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord. 2014 May; 3(3):408-12. PMID: 25876482.
      Citations: 4     Fields:    
    31. Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. IFN-? induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012 Jan 18; 242(1-2):39-46. PMID: 22112394.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    32. Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7. PMID: 21775738.
      Citations: 2     Fields:    Translation:Humans
    33. Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, Rivera VM. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011; 13(2):91-3. PMID: 24453710; PMCID: PMC3882955.
      Citations: 3     
    34. Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, Montague PR, Hutton GJ. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010; 4:219. PMID: 21152340; PMCID: PMC2996259.
      Citations: 11     
    35. Hong J, Hutton GJ. Regulatory effects of interferon-? on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010 Oct; 30(10):751-7. PMID: 20874252.
      Citations: 5     Fields:    Translation:HumansCells
    36. Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41. PMID: 19204263.
      Citations: 16     Fields:    Translation:Humans
    37. Hutton GJ, Avila M, Suarez GA. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009 Apr; 111(3):309-10. PMID: 19036497.
      Citations: 1     Fields:    Translation:Humans
    38. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008 Nov; 122(5):e1039-47. PMID: 18838462.
      Citations: 32     Fields:    Translation:Humans
    39. Hutton GJ, Su?rez Zambrano GA. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008 Oct; 65(10):1388-9. PMID: 18852359.
      Citations:    Fields:    Translation:Humans
    40. Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82. PMID: 18208877.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    41. Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain. 2008 Feb; 131(Pt 2):e89; author reply e90. PMID: 17908695.
      Citations: 1     Fields:    Translation:HumansCells
    42. Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9. PMID: 17401392.
      Citations: 20     Fields:    Translation:HumansCells
    43. Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005; 56:273-302. PMID: 15660513.
      Citations: 3     Fields:    Translation:Humans
    44. Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S3-11. PMID: 15596734.
      Citations: 7     Fields:    Translation:Humans
    45. Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, Zhang JZ. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004 Oct; 10(5):499-506. PMID: 15471364.
      Citations: 8     Fields:    Translation:HumansCells
    46. Wyss K, Hutton G, N'Diekhor Y. Costs attributable to AIDS at household level in Chad. AIDS Care. 2004 Oct; 16(7):808-16. PMID: 15385235.
      Citations: 9     Fields:    Translation:Humans
    47. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39. PMID: 15223245.
      Citations: 15     Fields:    Translation:HumansCells
    48. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008. PMID: 14985264.
      Citations: 28     Fields:    Translation:HumansCells
    49. Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002 Dec; 24(12):1998-2021. PMID: 12581542.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    HUTTON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (189)
    Explore
    _
    Co-Authors (21)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _